Renal grafts from anti‐hepatitis B core‐positive donors: a quantitative review of the literature

Mahboobi, Nastaran; Tabatabaei, Seyed Vahid; Blum, Hubert E.; Alavian, Seyed Moayed

doi:10.1111/j.1399-3062.2012.00782.x

Cited by 50 publications

(42 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(259,266,267) In a systematic review of studies that included 1,385 kidney recipients with organs from donors that were HBsAg negative but anti-HBc positive, 0.3% became HBsAg positive and 2.3% became anti-HBc positive. (267) The presence of anti-HBc and/or anti-HBs in the recipients is associated with protection against HBV seroconversion. (268) However, to reduce this small risk of HBV infection further, antiviral therapy should be administered to prevent de novo HBV infection.…”

Section: I Nonliver Solid Organ Transplant Recipientsmentioning

confidence: 99%

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

et al. 2018

View full text Add to dashboard Cite

Section: I Nonliver Solid Organ Transplant Recipientsmentioning

confidence: 99%

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

et al. 2018

View full text Add to dashboard Cite

“…50 In a review of nine studies with 1,385 evalu able HBsAgnegative recipients of kidneys from anti-HBcAg-positive donors, new HBV serologic markers were observed in only 45 (3.2%) patients and the rate of HBsAg acquisition was only 0.28% (four patients) with no evidence of symptomatic hepatitis. 51 This study did not explore the influence of recipient anti-HBsAg status or use of prophylactic therapy. Patient or graft outcomes were not worse among patients with HBsAg acquisition or evidence of anti-HBsAg or anti-HBcAg seroconversion.…”

Section: Viral Infectionsmentioning

confidence: 99%

Donor-derived infection—the challenge for transplant safety

Fishman¹,

Grossi

2014

Nat Rev Nephrol

View full text Add to dashboard Cite

Organ transplantation, including of the heart, lung, kidney, liver, pancreas, and small bowel, is considered the therapy of choice for end-stage organ failure. Each year, over 70,000 organs are implanted worldwide. One donor may provide multiple organs, as well as corneas and other tissues, for multiple recipients. The degree of risk for transmission of infection carried with grafts, notably of viruses, is largely unknown and, for a specific organ, difficult to assess. The approach to microbiological screening of organ donors varies with national and regional regulations and with the availability and performance of microbiological assays used for potential donors. Transmission of both expected or common, and unexpected infections has been observed in organ transplants, generally recognized after development of clusters of infections among recipients of organs from a common donor. Other than for unusual or catastrophic events, few data exist that define the incidence and manifestations of donor-derived infections or the ideal assays to use in screening to prevent such transmissions. Absolute prevention of the transmission of donor-derived infections in organ transplantation is not possible. However, improvements in screening technologies will enhance the safety of transplantation in the future.

show abstract

“…Evidence has shown that in solid organ transplantations such as kidney [42], bone marrow [43], and heart [44], HBV transmission is usually lower than 5%; while for recipients of liver transplants, a variable rate of de novo HBV infection occurs between 17% and 95% depending on the HBV serological markers of the donor [27, 37, 38, 45, 46]. However, the infection status of the recipient is also highly relevant, considering that among 4.4% and 17.6% of OBI has been reported in liver transplant recipients [28, 47–49].…”

Section: Introductionmentioning

confidence: 99%

Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia

et al. 2017

View full text Add to dashboard Cite

BackgroundHepatitis B virus (HBV) occult infection (OBI) is a risk factor to be taken into account in transfusion, hemodialysis and organ transplantation. The aim of this study was to identify and characterize at the molecular level OBI cases in patients with end-stage liver disease.MethodsSixty-six liver samples were obtained from patients with diagnosis of end-stage liver disease submitted to liver transplantation in Medellin (North West, Colombia). Samples obtained from patients who were negative for the surface antigen of HBV (n = 50) were tested for viral DNA detection by nested PCR for ORFs S, C, and X and confirmed by Southern-Blot. OBI cases were analyzed by sequencing the viral genome to determine the genotype and mutations; additionally, viral genome integration events were examined by the Alu-PCR technique.ResultsIn five cases out of 50 patients (10%) the criteria for OBI was confirmed. HBV genotype F (subgenotypes F1 and F3), genotype A and genotype D were characterized in liver samples. Three integration events in chromosomes 5q14.1, 16p13 and 20q12 affecting Receptor-type tyrosine-protein phosphatase T, Ras Protein Specific Guanine Nucleotide Releasing Factor 2, and the zinc finger 263 genes were identified in two OBI cases. Sequence analysis of the viral genome of the 5 OBI cases showed several punctual missense and nonsense mutations affecting ORFs S, P, Core and X.ConclusionsThis is the first characterization of OBI in patients with end-stage liver disease in Colombia. The OBI cases were identified in patients with HCV infection or cryptogenic cirrhosis. The integration events (5q14.1, 16p13 and 20q12) described in this study have not been previously reported. Further studies are required to validate the role of mutations and integration events in OBI pathogenesis.

show abstract

Renal grafts from anti‐hepatitis B core‐positive donors: a quantitative review of the literature

Abstract: Our review indicates that the risk of HBV transmission from HBcAb-positive kidney donors is extremely low. Therefore, kidneys from these donors can be transplanted safely into ESRD patients.

Cited by 50 publications

References 60 publications

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Donor-derived infection—the challenge for transplant safety

Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia

Contact Info

Product

Resources

About